News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 1304
- Sources here
- 15
- Companies here
- 14
Active search
1304 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AZZ (AZZ) reports recent Executive Compensation share sales
AZZ has filed a Form 144 notice detailing recent sales of its common stock through UBS Financial Services Inc. These transactions, categorized as Executive Compensation, include sales of 631 shares on April 24, 2026, and 1,106 and 940 shares on April 28, 2026. The …
Amazon.com, Inc. $AMZN Holdings Boosted by Hamilton Wealth LLC
Hamilton Wealth LLC increased its stake in Amazon.com, Inc. by 2.5% in the first quarter, owning 119,172 shares valued at $24.82 million. The article also details other institutional investor activity, significant insider stock sales by Amazon CEOs, and recent analyst ratings. It highlights both …
Sharemaestro market context Trend signal active 52 weeks +12.2%Key facts: Amazon.com, Inc. Anthropic Gain; AWS Sold Out; S&P Gains
Amazon's Q2 earnings were significantly boosted by the revaluation of its Anthropic stake. The company is facing high demand for AWS, with near-term capacity sold out, indicating a multi-year cloud infrastructure supply gap. Amazon also plans a significant investment in Poland for AI and …
Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen downgraded Maze Therapeutics (NASDAQ:MAZE) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Buy" with an average price target of $66.00. The company's shares opened at $27.18, representing a 1.8% decrease and significantly below its 52-week high …
Maze Therapeutics president sells $445,620 in company stock By Investing.com
Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 16,142 shares of company stock for $445,620 on August 13, 2026. This transaction followed an exercise of stock options at a lower price and was conducted under a Rule 10b5-1 trading plan. …
AZZ Inc COO Bryan Stovall Executes Sale of 2,677 Shares at $150.07 Average Price
Bryan Lee Stovall, COO of Metal Coatings at AZZ Inc (NYSE:AZZ), sold 2,677 shares of common stock at a weighted average price of $150.066 per share on August 14, 2026. After the sale, Stovall retains direct ownership of 35,000 shares. The transaction was not …
CCORF Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $29
CCORF has initiated coverage on Kazia Therapeutics (KZIA.US) with a Buy rating and set a price target of $29. This new rating suggests a positive outlook for the company's stock from CCORF.
H World Group Ltd expected to post earnings of 55 fen a share - Earnings Preview
H World Group Ltd (HTHT) is projected to report earnings of 55 fen per share. This article is an earnings preview from Reuters, providing a brief outlook on the company's upcoming financial results.
Amazon to pay $2.25M, revamp identity theft record requests under federal order
Amazon has agreed to pay a $2.25 million civil penalty and revise its process for handling identity theft record requests, following allegations that it violated the Fair Credit Reporting Act. The federal government accused Amazon of failing to provide victims with transaction records related …
Amazon reinstates binding arbitration, bars class-action lawsuits
By Greg Bensinger Aug 14 (Reuters) - Amazon on Friday reinstated binding arbitration for its U.S. customers while also barring them from seeking class-action lawsuits, making it more difficult for users to address grievances in court. In emails on Friday, Amazon said the changes …
AZZ Inc (AZZ) Insider Sell: Bryan Stovall Disposes of 2,677 Shares
Bryan Stovall, an insider at AZZ Inc (AZZ), sold 2,677 shares of the company on August 14, 2026, for approximately $401,737, bringing his direct ownership to 35,000 shares. This transaction is part of a broader trend of insider selling at AZZ Inc, with no …
H World Group Ltd (HTHT) Shares Surge 3.4% -- What GF Score of 71 Tells Investors
H World Group Ltd (HTHT) shares recently surged 3.4% to $41.88. The company is considered undervalued by its GF Value™ of $45.96 and holds a strong GF Score™ of 71/100, driven by excellent valuation and profitability sub-ranks. While gurus show mixed activity, there have …
Druckenmiller loads up on Amazon and AMD while dumping some chipmakers, 13F shows
Investing.com -- Stanley Druckenmiller's Duquesne Family Office executed a dramatic reshuffling of its portfolio during the latest quarter, highlighted by a massive rotation back into mega-cap technology and a decisive exit from several legacy semiconductor names. Most notably, the firm increased its core equity …
AZZ (NYSE:AZZ) COO Sells $401,737.39 in Stock
AZZ COO Bryan Lee Stovall sold 2,677 shares of the company's stock for a total of $401,737.39, reducing his direct ownership by 7.11%. The company recently reported strong quarterly earnings, beating analyst estimates, and increased its quarterly dividend. Analysts maintain a "Moderate Buy" rating …
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock
Maze Therapeutics' CMO, Harold Bernstein, sold 16,142 shares of company stock worth $445,680.62 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 50%. This follows a previous sale of 14,609 shares in July. Despite the insider selling and the company's ongoing unprofitability with …
Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan
Maze Therapeutics' President, R&D & CMO, Harold Bernstein, exercised 16,142 stock options and subsequently sold the resulting shares on August 13, 2026, under a Rule 10b5-1 trading plan. The options were exercised at $10.42 per share, and the common shares were sold at a …
Kazia Therapeutics (KZIA) investor group reports 4.6% beneficial stake via ADS
Lynwood Opportunities Master Fund, Lynwood Capital Management Inc., and Ben Shapiro have reported a beneficial ownership of 4.6% in Kazia Therapeutics (KZIA) through American Depositary Shares as of June 30, 2026. This stake represents 264,980,500 Ordinary Shares, with each ADS equivalent to 500 Ordinary …
Battery Ventures group trims Braze (BRZE) holdings to sub‑5% disclosed stakes
A group of Battery Ventures funds and certain managing members have filed an updated beneficial-ownership report for Braze, Inc. (BRZE), indicating that as of June 30, 2026, no single reporting person owns 5% or more of Braze’s Class A common stock. The filing details …
ParaZero Technologies (PRZO) outlines planned exit of VP Global Sales
ParaZero Technologies Ltd. (PRZO) has announced a separation agreement with its Vice President of Global Sales, Bat-Sheva Noy, effective August 17, 2026. The company stated that her departure is not due to any disagreements with operations, policies, or practices, and ParaZero does not expect …